Keith A Vossel

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi New approaches to the treatment of frontotemporal lobar degeneration
    Keith A Vossel
    Department of Neurology, Memory and Aging Center, University of California, San Francisco, California 94143 1207, USA
    Curr Opin Neurol 21:708-16. 2008
  2. ncbi ApoE and TDP-43 neuropathology in two siblings with familial FTLD-motor neuron disease
    Keith A Vossel
    a Department of Neurology, University of California, San Francisco, CA, USA
    Neurocase . 2012
  3. ncbi Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model
    Pascal E Sanchez
    Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA
    Proc Natl Acad Sci U S A 109:E2895-903. 2012
  4. ncbi Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia
    Federica Agosta
    Memory and Aging Center, Department of Neurology, University of California, 350 Parnassus Avenue, Suite 905, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 106:2018-22. 2009
  5. ncbi Tau reduction prevents Abeta-induced defects in axonal transport
    Keith A Vossel
    Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA
    Science 330:198. 2010

Collaborators

Detail Information

Publications5

  1. ncbi New approaches to the treatment of frontotemporal lobar degeneration
    Keith A Vossel
    Department of Neurology, Memory and Aging Center, University of California, San Francisco, California 94143 1207, USA
    Curr Opin Neurol 21:708-16. 2008
    ..Treatment approaches for frontotemporal lobar degeneration (FTLD) are rapidly evolving with improved understanding of the disease. This brief review highlights recent advances...
  2. ncbi ApoE and TDP-43 neuropathology in two siblings with familial FTLD-motor neuron disease
    Keith A Vossel
    a Department of Neurology, University of California, San Francisco, CA, USA
    Neurocase . 2012
    ..Although differences seen in a sibling pair could arise due to chance, these findings raise the possibility that apoE4 exacerbates brain pathology in FTLD through formation of neurotoxic apoE fragments and interactions with TDP-43...
  3. ncbi Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model
    Pascal E Sanchez
    Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA
    Proc Natl Acad Sci U S A 109:E2895-903. 2012
    ..Our findings support the hypothesis that aberrant network activity contributes causally to synaptic and cognitive deficits in hAPP mice. LEV might also help ameliorate related abnormalities in people who have or are at risk for AD...
  4. ncbi Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia
    Federica Agosta
    Memory and Aging Center, Department of Neurology, University of California, 350 Parnassus Avenue, Suite 905, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 106:2018-22. 2009
    ..The atrophy patterns in epsilon4 carriers may indicate that they are at greater risk for clinical progression...
  5. ncbi Tau reduction prevents Abeta-induced defects in axonal transport
    Keith A Vossel
    Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA
    Science 330:198. 2010
    ..Lowering tau levels prevented these defects without affecting baseline axonal transport. Thus, Aβ requires tau to impair axonal transport, and tau reduction protects against Aβ-induced axonal transport defects...